C3i was proud to participate in Advanced Therapies Week, which took place in Dallas from January 20 to 23, 2025.
As a key event in the biotech industry, ATW 2025 gathered 2,500 attendees, 100 investors, 600 biotech companies, and 180 exhibitors at the Kay Bailey Hutchinson Convention Center. With six content tracks and 250 expert speakers, the event fostered innovation, regulatory discussions, and strategic collaborations to advance the future of cell and gene therapies.
This conference, organized by Phacilitate, provided a valuable opportunity to connect with industry leaders, share knowledge, and stay at the forefront of what we do best: bringing life-saving cell therapies from the laboratory to the clinic.
C3i was on the ground at ISSCR 2026 in Montréal, where one message came through clearly: cell and gene therapy is moving from scientific promise to clinical and commercial reality. Academia and industry have taken meaningful steps forward this past year, and the momentum is building. A few takeaways stood out: Clinical progress is accelerating […]
The C3i team recently wrapped up a busy week at the BIO International Convention in San Diego, where renewed investment, artificial intelligence, and cross-border collaboration set the tone for biotech in the year ahead. Three themes stood out on the show floor: A rebounding market. Investment is picking up across the biotech ecosystem, and with […]
For the first time in Canada, blood stem cells were genetically modified using CRISPR-Cas9 technology and subsequently injected into patients as part of a North American clinical trial targeting acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Every graft used in this landmark study was produced in Montreal, at Hôpital Maisonneuve-Rosemont, through the biomanufacturing expertise […]
